Analysts Set Autolus Therapeutics Ltd – (NASDAQ:AUTL) PT at $42.67
Shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) have been assigned an average rating of “Buy” from the five analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $45.50.
A number of research analysts have weighed in on AUTL shares. William Blair started coverage on American Software in a report on Wednesday, April 3rd. They set an “outperform” rating and a $12.03 target price for the company. Zacks Investment Research raised General Moly from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. Finally, HC Wainwright set a $18.00 price objective on Sutro Biopharma and gave the stock a “buy” rating in a report on Friday, May 17th.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Exane Derivatives purchased a new position in shares of Autolus Therapeutics during the second quarter worth about $50,000. Marshall Wace LLP grew its holdings in shares of Autolus Therapeutics by 93.4% during the first quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock worth $7,330,000 after purchasing an additional 112,489 shares in the last quarter. CWM LLC purchased a new position in shares of Autolus Therapeutics during the first quarter worth about $1,105,000. Barclays PLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $113,000. Finally, Geode Capital Management LLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $322,000. 43.37% of the stock is owned by institutional investors.
Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.11). The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts expect that Autolus Therapeutics will post -3.07 earnings per share for the current fiscal year.
About Autolus Therapeutics
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.